Stanford is running 37,000 AI agents as a virtual biotech — and one of its drug designs got independently confirmed by Merck

Stanford professor James Zou says AI research is moving from single-agent workflows to large organizations of collaborating agents. His team built a Virtual Biotech with tens of thousands of specialized agents for tasks like target discovery, molecule design, and clinical planning, after earlier AI-designed nanobodies outperformed human-designed ones in lab tests.

The work points to a shift from AI as an individual productivity tool toward agent orchestration that mirrors complex institutions. If validated at scale, such systems could compress early drug discovery timelines while creating new demand for infrastructure that connects scientific databases, simulation environments, and multi-agent governance.